Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors

Inclusion Criteria: * Age \>= 1 year old and =\< 21 years old; * Refractory solid tumors, histologically proven at diagnosis (no additional biopsy needs to be performed for the purpose of the study); * Relapsed or refractory solid tumors after standard treatment or phase II, III-IV clinical trials treatment have failed; * Karnofsky or Lansky status \>= 70%; * Life expectancy \>= 8 weeks; * No chemotherapy / radiotherapy within 4 weeks before entry into the study; * Adequate biological parameters : * Absolute neutrophil count \>= 1.0 x 109/L; * Platelet count \>= 100 x 109/L; * Hemoglobin \>= 8 mg/dL; * Total bilirubine =\< 1.5 ULN; * Transaminases =\< 2.5 ULN (=\< 5 ULN in case of liver metastases); * Creatinine clearance (Cockroft) \>= 70 mL/min/1.73 m2; * Normal coagulation profile with prothrombin \>= 70%, TCA =\< 35 and fibrinogen \>= 2 g/L; * Patients with 1 to 3 previous therapeutic lines are eligible; * No current grade \>= 2 organ toxicity based on NCI-CTCAE version 3.0; * All patients with reproductive potential must have an effective method of birth control while on study; * Negative pregnancy test in females when indicated; * Informed written consent signed by patients or their parents or legal guardians; * Patient who was informed of the results of prior medical consultation; * Patient having a social insurance. Exclusion Criteria: * Patient with a constitutional anomaly of coagulation and/or of hemostasis (type hemophilia, von Willebrand disease, congenital clotting factor deficit, platelet disorder), exposing them to increased risk of bleeding; * Pre-treatment with a mTOR inhibitor; * Other simultaneous malignancy; * Concurrent administration of any other anti-tumour therapy; * Known hypersensitivity or contraindication to study drugs or ingredients; * Severe concomitant disease (e.g. infection disease); * Patient unable for medical follow-up; * Pregnancy and/or lactation; * Patient included in another clinical drug trial; * Patient taking drugs interfering with pharmacology of rapamycin and/or irinotecan (e.g. drugs interfering with CYP3A4); * Patient under judicial protection.